新华社日内瓦9月10日电（记者王露）总部位于日内瓦的全球防治艾滋病、结核病和疟疾基金会（下称 全球基金会）10日发布年度成果报告说，该基金会自2002年成立以来，与合作伙伴共同努力，在艾滋 病、结核病和疟疾防治方面取得重要进展，已成功挽救7000万人的生命。 报告显示，在艾滋病防治方面，2024年，在全球基金会资助的国家和地区，艾滋病病毒感染者中有88% 知晓自身感染状况，79%在接受抗逆转录病毒治疗，74%病毒载量得到抑制，相关指标均创下历史新 高。自2002年以来，在全球基金会资助的国家和地区，与艾滋病相关死亡率已下降82%，艾滋病发病率 下降73%。 全球基金会执行主任彼得·桑兹在一份新闻公报中说，这证明凭借正确的工具、坚实的伙伴关系和持续 投入，我们能够改善全球卫生的发展进程。他呼吁全球卫生界加快行动，减少碎片化和重复性工作，为 各方合作提供便利。 全球基金会是在全球范围内为抗击艾滋病、结核病和疟疾提供资助的非营利性机构，于2002年在联合国 倡议下成立。据介绍，2024年全球基金会向100多个国家和地区投入27亿美元用于加强疾病监测和防 控。 报告同时警告，资金压力、地区冲突等使疾病防控面临新挑战。 ...

Core Viewpoint - The company, Eddie Pharmaceuticals, is making significant advancements in the development of HIV treatments, particularly focusing on the new generation of integrase inhibitors and long-acting preventive medications, while also expanding its human protein business. Group 1: HIV Treatment Development - The company has completed a Phase I/IIa clinical study for its new integrase inhibitor, CC017, showing a significant viral load reduction of 2.34 Log10 copies/mL after 10 days of monotherapy, with over 90% of participants achieving complete viral suppression after 18 days of combination therapy [2] - The company reported a 58.49% year-on-year increase in sales revenue for its HIV new drugs, reaching 129 million yuan in the first half of 2025, indicating successful commercialization efforts [3] - The company is actively participating in academic conferences to promote its products and enhance its brand image, while also focusing on patient education and team optimization to improve treatment quality and service processes [3] Group 2: Long-Acting Preventive Medications - The company is accelerating the development of long-acting HIV medications, responding to national strategies for HIV prevention, with two new long-acting drug patents filed and accepted [4] - The market for long-acting medications is expected to grow due to their lower side effects and better privacy, positioning the company to capture a significant share of the pre-exposure prophylaxis (PrEP) market [4] Group 3: Human Protein Business Expansion - The company has established strong relationships with upstream suppliers and is integrating operations following the acquisition of Nanda Pharmaceutical, which has positively impacted its revenue and profitability [6] - The human protein market is growing, with significant advancements in collaboration with Nanda Pharmaceutical, including the approval of new drug applications for innovative human protein products [7] Group 4: Financial Performance - The company's mid-2025 report shows a 100.19% increase in main revenue to 362 million yuan and a 120.23% increase in net profit to 9.19 million yuan [8] - The second quarter of 2025 saw a revenue increase of 86.71% year-on-year, indicating strong financial performance despite some negative net profit figures [8]

Core Viewpoint - The recent "Red Sister" incident in Nanjing has heightened anxiety about infectious diseases, particularly HIV, with over 1.35 million reported cases in China as of December 31, 2024, marking a year-on-year increase of 65,000 cases [1] Group 1: HIV Awareness and Public Response - The fear surrounding HIV has led to irrational behaviors, such as individuals seeking expensive preventive treatments and experiencing psychological distress [1] - There is a significant lack of awareness about HIV transmission, with youth and the elderly becoming high-risk groups due to improper use of protection [1] - The online community "Fear of AIDS Bar" has nearly 170,000 users sharing similar fears, indicating a widespread psychological phenomenon known as "fear of AIDS" affecting an estimated 1.6 million people in China [5] Group 2: Preventive Treatments and Costs - Lenacapavir, a long-acting injection developed by Gilead Sciences, was approved in China and costs approximately 200,000 RMB per year, providing nearly 100% prevention against HIV [2][19] - PrEP (pre-exposure prophylaxis) is used by individuals at high risk, reducing the likelihood of HIV infection by over 90% when taken consistently [5] - The cost of PrEP is around 10 RMB per day, but adherence to the medication regimen poses a significant challenge for many users [5][10] Group 3: Market Dynamics and Drug Accessibility - The global market for anti-HIV drugs was valued at $43.1 billion in 2023 and is expected to reach $48.4 billion by 2025, with China holding a small market share of 1-2% [12][16] - The domestic market is primarily composed of imported and generic drugs, with major companies like Gilead, GSK, and Johnson & Johnson controlling 80% of the market [12] - The introduction of generic drugs is expected to significantly reduce the cost of PEP (post-exposure prophylaxis) treatments, potentially halving prices from over 2,000 RMB to around 1,000 RMB after certain patents expire [13][19] Group 4: Education and Public Health Initiatives - There is a pressing need for increased public education on HIV, as many misconceptions persist, particularly among youth and the elderly [16][17] - Initiatives like the "Zero AIDS Youth" campaign aim to raise awareness and provide free testing, highlighting the importance of education in preventing HIV transmission [16] - The U=U (Undetectable = Untransmittable) concept is crucial for reducing stigma and encouraging treatment adherence among HIV-positive individuals [18]